

BIO-ENTREPRENEUR 2004
LES HAUTES TECHNOLOGIES BIOTECH ET SANTE :
DEUX PAYS : DES ATOUTS RESPECTIFS COMPARES :
DES RAISONS DE S'IMPLANTER

**« Drug Companies in France
and Japan »**

- 16 march 2004 -

Dr Pierre Le Sourd
Leem President

Biotechnology: A quantum leap for Tomorrow-Innovation in Pharmaceuticals

- Biotherapeutics represent a growing and significant portion of launches
 - 155 Biotech products on the market in 2002
 - 39 % of New Molecular Entities launched in 2001
- As a result, two kinds of future drugs
 - High-Innovative Drugs, patient-tailored
 - Classical Drugs for large populations
- With an accelerated development
- A new growth lever ?
 - A growing segment with 20 % per year
 - A growing manufacturing industry

Biotechnology: The heart of the battle

- The US take a strong hold on the industry
 - 52 % of the patents
 - 60 % of the biotech sales
- Japanese and European biotechnologies are on the move
 - A growing number of biotech companies
 - + 48,2 % since 1998 in Japan
 - A very high number of new businesses created during the last four years in France (e.g. 240 companies in Health sector)
 - Biotech Sales Percentage by Country
 - Japan with 10 % is ranked number 2
 - France with 5 % is ranked number 4

Japanese biotech: a model-to-follow

- A dynamic policy in favour of biotechnology
 - At national level:
 - The Biotechnology Strategy Council has been created in 2002 and led by the Prime Minister himself
 - A favourable regulatory scheme : Embryonic Stem Cell for therapeutics use
 - At regional level:
 - Strong Bio-Clusters
- A general policy in favour of Research as a key factor of competitiveness
 - A double budget for the Public Research
 - 3,18 % of the GDP for Research / 3,4 % projected in 2006
 - Public incentives for Private Research
 - Tax incentive system
 - Strengthening of the Intellectual Property Rights

France: now in a favourable environment for Biotech development

- At European and National levels
 - A European strategy for biotechnology
 - E.g. 6th Framework Research Programme (2002-2006)
 - A national plan to develop a favourable field for the development of biotech companies
 - The creation of the “Nouveau Marché” in 1996
 - “Loi sur l’Innovation” in 1999
 - “Plan Innovation 2003”
- At Regional Level
 - Creation of 3-5 Bio-Clusters projected in the Plan “Haigneré”
- At private Level
 - Leem and Biotech companies involved in the development of the Biotech :
 - ➔ *Creation of the Biotechnology Committee at the Leem*
- For the research in general, France targets the Lisbon Objective : “ *To make the EU the most competitive and dynamic knowledge-based economy in the world by 2010*”

We have now to develop...

- Biotechnology is a major opportunity to increase competitiveness of our national industries
- Biotechnology is a networking industry
 - We have to know each other and to develop synergy in order to compete the US
- How can we work together ?
 - Existing annual meetings JPMA-LEEM
 - Developing this kind of event

